Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 376-382

  Pirker, R ^a   Pereira, J R ^b   Szczesna, A ^c   von Pawel, J ^d   Krzakowski, M ^e   Ramlau, R ^f   Vynnychenko, I ^g   Park, K ^h   Eberhardt, W E E ⁱ   de Marinis, F ^j   Heeger, S ^k   Goddemeier, T ^k   O'Byrne, K J ^l   Gatzemeier, U ^m  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Instituto do Cancer Dr Arnaldo   (Brazil)

^c Division III   (Poland)

^d Pneumology Clinic   (Germany)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g SUMY STATE UNIVERSITY   (Ukraine)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k MERCK KGAA   (Germany)

^l ST JAMES S HOSPITAL   (Ireland)

^m KRANKENHAUS GROSSHANSDORF   (Germany)

more..

Author keywords

Biomarker; Cetuximab; Chemotherapy; Lung cancer; NSCLC; Prognostic factor

Indexed keywords

CETUXIMAB; CISPLATIN; NAVELBINE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863778954     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.010     Document Type: Article

References (27)

1. Bunn P.A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 2002, 20:23S-33S.
2. Bunn P.A., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 2008, 13(Suppl. 1):37-46.
3. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
4. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
5. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
6. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
7. Collet D. Modelling survival data in medical research 1994, Chapman & Hall, London, p. 78-85.
8. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122:1037-1057.
9. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65:25-32.
10. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986, 4:702-709.
11. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9:1618-1626.
12. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995, 13:1221-1230.
13. Hsu L.H., Chu N.M., Liu C.C., Tsai S.Y., You D.L., Ko J.S., et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor. Lung Cancer 2009, 66:262-267.
14. Shinkai T., Eguchi K., Sasaki Y., Tamura T., Ohe Y., Kojima A., et al. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992, 30:1-6.
15. Sculier J.P., Chansky K., Crowley J.J., Van Meerbeeck J., Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol 2008, 3:457-466.
16. Hoang T., Xu R., Schiller J.H., Bonomi P., Johnson D.H. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005, 23:175-183.
17. Hirsch F.R., Spreafico A., Novello S., Wood M.D., Simms L., Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481.
18. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009, 4:1568-1571.
19. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
20. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
21. Tsao A.S., Liu D., Lee J.J., Spitz M., Hong W.K. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006, 106:2428-2436.
22. Janjigian Y.Y., McDonnell K., Kris M.G., Shen R., Sima C.S., Bach P.B., et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010, 116:670-675.
23. Ou S.H., Ziogas A., Zell J.A. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009, 4:1083-1093.
24. Calvo E., Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006, 24:2158-2163.
25. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009, 39:137-150.
26. O'Byrne K.J., Gatzemeier U., Bondarenko I., Barrios C., Eschbach C., Martens U.M., et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 12:795-805.
27. Pirker R., Pereira J., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. Epidermal growth factor receptor expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13:33-42.